{
}
BioAge Labs has entered a multi-year partnership with Novartis to tackle age-related diseases, potentially worth up to $550 million. The collaboration will leverage BioAge's human longevity datasets and Novartis's expertise in exercise biology to discover new therapeutic targets and explore the biological mechanisms of aging. This agreement follows BioAge's recent IPO and the discontinuation of a phase 2 obesity trial due to safety concerns.
BioAge Labs has announced a multi-year collaboration with Novartis to discover novel therapeutic targets for age-related diseases, leveraging BioAge's extensive human longevity data and Novartis's expertise in exercise biology. The partnership includes up to $20 million in upfront payments and research funding, with potential future milestones totaling up to $530 million. This collaboration aims to explore the biological mechanisms of aging and the benefits of physical exercise to develop transformative therapies.
BioAge Labs has entered a multi-year collaboration with Novartis to discover novel therapeutic targets for age-related diseases, leveraging BioAge's extensive human longevity data and Novartis's expertise in exercise biology. The partnership could yield up to $550 million in funding and milestone payments, aiming to enhance treatment options for aging-related conditions.
Novartis has partnered with BioAge Labs in a multi-year collaboration to discover new therapies for age-related diseases, involving up to $20 million in funding and potential milestones of $530 million. The partnership will leverage BioAge’s extensive human longevity datasets and advanced analytics to identify healthy lifespan determinants. This collaboration comes after BioAge faced a setback with its lead asset, azelaprag, which was discontinued due to safety concerns in a recent study.
Michaela Kneissel
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
novartis and bioage partner to tackle age-related diseases in major deal
United States Dollar
Novartis AG
Amgen Inc.
BioAge Labs, Inc.
Eli Lilly and Company
USA
CHE
Lai Peng Leong
Michaela Kneissel
Kristen Fortney
Show more
16:44 18.12.2024
bioage labs partners with novartis to target age-related diseases through research
15:11 18.12.2024
bioage labs and novartis collaborate to target age-related diseases through exercise biology
15:00 18.12.2024
novartis partners with bioage labs to explore therapies for age-related diseases
14:45 18.12.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Finance Mergers & Acquisitions
Hedge Funds & Private Equity
Global Trade Developments
Global Financial Events
Market Analysis and Predictions
Financial Scams and Security
Government Policies
Banking Regulations
CEO Changes
Startups & Entrepreneurship
Economic Sanctions
Retail and Consumer Goods
Industry Mergers & Acquisitions
Central Bank Actions
Workplace Trends
International Relations
Government Economic Policies
Countries:
Companies:
JPMorgan Chase & Co.
Tesla, Inc.
The Goldman Sachs Group, Inc.
Wells Fargo & Company
Bank of America Corporation
Apple Inc.
Barclays PLC
Citigroup Inc.
Morgan Stanley
Berkshire Hathaway Inc.
Microsoft Corporation
SpaceXCoin USD
The Charles Schwab Corporation
AMERICAN EXPRESS
Amazon.com, Inc.
U.S. Bancorp
UBS Group AG
Banco Santander, S.A.
Deutsche Bank Money Market PP
Citizens, Inc.
Currencies:
United States Dollar
Euro
Indian Rupee
Chinese Yuan
Japanese Yen
British Pound Sterling
South Korean Won
Swiss Franc
United Arab Emirates Dirham
Canadian Dollar
Israeli New Shekel
Swedish Krona
Mexican Peso
New Taiwan Dollar
Egyptian Pound
People: